Body as a Whole: allergy, fever, leg pain, malaise, chest pain.
Cardiovascular: palpitation, dependent edema, angina pectoris, leg edema, abnormal ECG, hypertension, peripheral edema.
CNS: insomnia, somnolence, migraine, vertigo, paresthesia, involuntary muscle contractions, hypoaesthesia.
Gastrointestinal: flatulence, constipation, gastritis, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, non-specific gastrointestinal disorders.
Metabolic: gout, hypercholesterolemia, diabetes mellitus.
Musculoskeletal: arthritis, arthralgia, leg cramps, myalgia.
Psychiatric: anxiety, depression, nervousness.
Resistance Mechanism: infection, fungal infection, abscess, otitis media.
Respiratory: asthma, rhinitis, dyspnea, epistaxis.
Skin: dermatitis, eczema, pruritus.
Urinary: micturition frequency, cystitis.
Vascular: cerebrovascular disorder.
Special Senses: abnormal-vision, conjunctivitis, tinnitus, earache.
A single case of angioedema was reported (among a total of 3781 patients treated with telmisartan).
Hydrochlorothiazide: Adverse experiences that have been reported with hydrochlorothiazide, without regard to causality, are listed as follows: Body as a whole: weakness.
Digestive: pancreatitis, jaundice (intrahepatic cholestatic jaundice), sialadenitis, cramping, gastric irritation.
Hematologic: aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia.
Hypersensitivity: purpura, photosensitivity, urticaria, necrotizing angiitis (vasculitis and cutaneous vasculitis), fever, respiratory distress including pneumonitis and pulmonary edema, anaphylactic reactions.
Metabolic: hyperglycemia, glycosuria, hyperuricemia.
Musculoskeletal: muscle spasm.
Nervous System/Psychiatric: restlessness.
Renal: renal failure, renal dysfunction, interstitial nephritis.
Skin: erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis.
Special Senses: transient blurred vision, xanthopsia.
Clinical Laboratory Findings: In controlled trials, clinically relevant changes in standard laboratory test parameters were rarely associated with administration of PACSARTAN-TH tablets.
View ADR Monitoring Form